Printer Friendly

Aventis obtains United States patent.

Aventis Pharmaceuticals, Inc. (Bridgewater, NJ) has patented a highly efficient, high-throughput method for the identification and elimination of redundancy in a population of nucleic acid molecules using microarrays. This method involves a reiterative subtraction protocol that creates a library that becomes more biased toward unknown genes with each successive round. The removal of repetitive and previously characterized nucleic acids from the library allows the identification of low-abundance mRNA from sources of interest and enhances the rate of novel gene discovery. The present invention is also useful for the removal of contaminating nucleic acids from cloning libraries. (US 6,638,717)
COPYRIGHT 2003 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Aventis Pharmaceuticals
Publication:BIOTECH Patent News
Article Type:Brief Article
Geographic Code:1USA
Date:Oct 1, 2003
Previous Article:Toyo Boseki obtains United States patent.
Next Article:Plant Bioscience obtains United States patent.

Related Articles
Aventis says antitrust lawsuit is baseless.
Aventis to move forward with reissuance process for contested Lovenox patent.
Sanofi-Aventis receives allowance on reissuance application for Lovenox '618 patent.
Update on patent ltigation schedule in the United States for Plavix.
Plavix litigation settlement agreement amended.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters